InVivo Therapeutics’ Chapter 11 cases closed on March 31, 2026 under a final decree Dkt. 403, following a liquidation that provided for equity distributions. The decree preserved the trustee’s duties to complete final distributions and specified reporting and fee obligations; the final claims register Dkt. 406 followed on April 22, 2026.

InVivo Therapeutics Corporation’s Chapter 11 cases closed on March 31, 2026, following implementation of a liquidating plan. The final decree Dkt. 403 discharged the liquidation trustee and its professionals from their duties except for final distributions and compliance with the decree, including remaining reporting and fee obligations. Verita filed the final claims register Dkt. 406 on April 22, 2026.

The company filed for Chapter 11 on February 1, 2024 after abandoning development of its Neuro-Spinal Scaffold implant for spinal cord injuries. According to Richard Christopher’s first-day declaration Dkt. 3, the INSPIRE 2.0 trial failed its primary endpoint in March 2023, and efforts to obtain financing or pursue strategic alternatives did not produce a viable path forward. InVivo entered bankruptcy with approximately $5.4 million in cash and planned to finance an orderly wind-down without debtor-in-possession financing.

The court confirmed the joint liquidation plan Dkt. 246 on June 21, 2024, establishing a liquidation trust to administer remaining assets, resolve claims and make distributions. The court subsequently authorized an asset sale to Globus Medical Dkt. 261 on July 8, 2024. The plan reached effectiveness on July 12, 2024, as recorded in the effective-date notice Dkt. 270.

The liquidation ultimately provided for a return to equity holders. The court authorized Class 6 equity distributions Dkt. 383 on November 18, 2025. The trustee’s December 30, 2025 amended distribution notice Dkt. 395 stated that assets remained available for equity after claims administration and set a distribution of $0.5991495 per share, with a December 30 record date and January 9, 2026 payment date. Separately, the quarterly report filed January 16, 2026 Dkt. 398 reported priority claims paid at 100% and general unsecured claims at 97% as of December 31, 2025. The March 2026 final decree retained authority for final distributions after closure.

InVivo Therapeutics’ Chapter 11 cases closed on March 31, 2026 under a final decree Dkt. 403, following a liquidation that provided for equity distributions. The decree preserved the trustee’s duties to complete final distributions and specified reporting and fee obligations; the final claims register Dkt. 406 followed on April 22, 2026.

InVivo Therapeutics Corporation’s Chapter 11 cases closed on March 31, 2026, following implementation of a liquidating plan. The final decree Dkt. 403 discharged the liquidation trustee and its professionals from their duties except for final distributions and compliance with the decree, including remaining reporting and fee obligations. Verita filed the final claims register Dkt. 406 on April 22, 2026.

The company filed for Chapter 11 on February 1, 2024 after abandoning development of its Neuro-Spinal Scaffold implant for spinal cord injuries. According to Richard Christopher’s first-day declaration Dkt. 3, the INSPIRE 2.0 trial failed its primary endpoint in March 2023, and efforts to obtain financing or pursue strategic alternatives did not produce a viable path forward. InVivo entered bankruptcy with approximately $5.4 million in cash and planned to finance an orderly wind-down without debtor-in-possession financing.

The court confirmed the joint liquidation plan Dkt. 246 on June 21, 2024, establishing a liquidation trust to administer remaining assets, resolve claims and make distributions. The court subsequently authorized an asset sale to Globus Medical Dkt. 261 on July 8, 2024. The plan reached effectiveness on July 12, 2024, as recorded in the effective-date notice Dkt. 270.

The liquidation ultimately provided for a return to equity holders. The court authorized Class 6 equity distributions Dkt. 383 on November 18, 2025. The trustee’s December 30, 2025 amended distribution notice Dkt. 395 stated that assets remained available for equity after claims administration and set a distribution of $0.5991495 per share, with a December 30 record date and January 9, 2026 payment date. Separately, the quarterly report filed January 16, 2026 Dkt. 398 reported priority claims paid at 100% and general unsecured claims at 97% as of December 31, 2025. The March 2026 final decree retained authority for final distributions after closure.